Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Method Developed to Diagnose Hereditary Breast and Ovarian Cancer

Published: Wednesday, January 16, 2013
Last Updated: Wednesday, January 16, 2013
Bookmark and Share
Massive sequencing algorithm and bioinformatic analysis to detect very efficiently genetic mutations linked to the disease.

Researchers of the Catalan Institute of Oncology (ICO) at the Bellvitge Biomedical Research Institute (IDIBELL) have developed and validated a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The model is based on a genetic analysis and bioinformatics which has been proved very effective. The new protocol has been described in an article published in the European Journal of Human Genetics.
 
In recent years, new advances in sequencing techniques have involved the development of new platforms for nucleic acid sequencing, called mass sequencing platforms or next sequencing generation. These technological improvements have brought a revolution in biomedical research, in the field of genetics and genomics. The emergence of next-generation sequencers and the possibility of combining samples from different patients, using identifiers have allowed adapt these new technologies in the field of genetic diagnostics.
 
Using a platform of the last generation mass sequencing, the team led by the researcher Conxi Lázaro, from the Hereditary Cancer Program at the ICO and IDIBELL, has developed a comprehensive protocol that allows sequenced all coding regions and adjacent regions of BRCA1 and BRCA2 genes, responsible for hereditary breast and ovarian cancer.
 
 Mass sequencing algorithm

 
"This approach has identified all point mutations and small deletions and insertions analyzed, even in regions of high technical difficulty, such as homopolymeric regions", explains the ICO-IDIBELL researcher. The developed protocol is an own algorithm of mass sequencing and bioinformatics analysis that has been shown to be very efficient in the detection of all existing mutations and to eliminate false positives.
 
The validation of this algorithm to diagnose hereditary breast and ovarian cancer syndrome has shown a sensitivity and specificity of 100% in the analyzed samples, while reducing costs and time for obtaining the results.
 
Furthermore, the research team led by Lázaro has implemented the use of this approach for the responsible genes for hereditary colorectal cancer, such as familial polyposis and Lynch syndrome.
 
Up to ten percent of cancers are hereditary, which means they are transmitted from parents to children the genetic mutations predisposing to various types of tumors. The identification of these mutations is very important to prevent the occurrence of tumors in people who have familial predisposition.
 
The hereditary breast and ovarian cancer syndrome is one of the hereditary cancer types that affects more people. The disease is caused by mutations in the BRCA1 and BRCA2 genes. These mutations are also associated with other kind of cancers.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Researchers Discover the Genetic Signature of Highly Aggressive Small Lung Tumors
A study conducted by the IDIBELL allows to identify this type of cancer at an early stage and adapt the treatment.
Thursday, October 03, 2013
IDIBELL and ICFO Researchers Develop Technology that Predicts Metastasis in Breast Cancer
Raman is a promising microspectroscopy technique for identifying metastatic phenotype of breast cancer cells from their lipid profile.
Monday, October 22, 2012
Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!